Abstract The anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity, associated with a persistent positivity for anti-phospholipid antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus anti-coagulant (LA), anti-cardiolipin (aCL), and anti-b2 glycoprotein-I (b2GPI). To date, the therapeutic approach for thrombotic APS mainly centers on long-term anti-coagulation with a vitamin K antagonist (VKA). APS management may represent a challenge for the treating physicians. Patients with different aPL profiles need a tailored risk-stratified approach. Moreover, in patients with recurrent thrombotic events despite therapy with VKA, or in those with microvascular involvement, new therapeutic options are highly needed. In this review, we aim to elucidate recent findings about new aPL specifities, available risk scoring models, and novel therapeutic approaches in APS management.
Introduction
The anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis (arterial and/ or venous) and/or pregnancy morbidity (miscarriages and late pregnancy complications, such as fetal deaths and premature births) associated with a persistent positivity for antiphospholipid antibodies (aPL). The current classification criteria for APS include three laboratory tests: lupus anticoagulant (LA), anti-cardiolipin (aCL), and anti-b2 glycoprotein-I (b2GPI). However, growing evidences are supports that in some selected cases, non-criteria aPL may also play a role. To prevent detection of transient antibodies, tests must be positive C2 occasions, at least 12 weeks apart.
Albeit the pathogenesis of APS has not been fully clarified, some of the key mechanisms have been recently described. Thrombotic events are one of the major disease features, and are determined by multiple mechanisms, including activation of endothelial cells, monocytes, platelets, coagulation, and complement pathways in addition to inhibition of fibrinolytic and anti-coagulation pathways. Recent evidence indicates that vasculopathy, enhanced mainly by severe intimal hyperplasia, can also play a role in arterial vascular occlusion (due to stenotic lesions) and pregnancy morbidity.
Herewith, we aim to discuss our point of view on new insights in APS, including laboratory testing, thrombotic risk assessment, and upcoming therapeutic options.
Role of new antibody specificities
In the current clinical practice, aCL antibodies, anti-b2GPI antibodies and the LA have been the most established tests for the diagnosis of APS [1] . The clinical utility of aPL assays for autoantibodies other than the routinely used one is currently under debate. Indeed, current lines of research are examining the usefulness of testing for new aPL specificities in identifying APS in patients with thrombosis and/or pregnancy morbidity, particularly in those who are repeatedly negative for the criteria aPL. Among the socalled extra-criteria aPL tests, anti-phrothrombin (aPT) [and mainly anti-phosphatidylserine/prothrombin (aPS/ PT)] antibodies and anti-b2GPI glycoprotein-I domain 1 (anti-b2GPI-DI) antibodies have been proposed to potentially improve the diagnostic accuracy, and, especially when assessing the risk for both thrombosis and pregnancy morbidities in patients suspected of APS. Other antibody specificities, such as anti-annexin A5 and antivimentin antibodies, might be considered for thrombotic risk assessment only in selected patients, in particular when other aPL tests are negative, in the presence of clinical APS signs and/or symptoms. Further investigations are needed to assess their role in the diagnostic algorithm for APS.
Anti-b2GPI glycoprotein-I domain 1 antibodies
Although the physiological functions of b2GPI are still uncertain, available evidence supports a pathogenic role for anti-b2GPI antibodies contributing to thrombosis and pregnancy morbidity. However, not all patients positive for the presence of anti-b2GPI antibodies develop clinical aPL-related manifestations. This heterogeneity in the pathogenic potential of anti-b2GPI antibodies may be ascribed to the molecular structure of b2GPI, presenting multiple antigenic specificities that can be targeted by different autoantibodies. The b2GPI has five homologous domains (D1 to D5), and the main epitope that has been found to be associated with APS, involves regions of D1 and growing evidence, both in vivo and in vitro, has resulted in the identification of domain I as the ''immunodominant epitope'' [2] , supporting a role for anti-b2GPI-DI antibodies in the development of APS-related clinical manifestations.
Recently, a systematic review that included a total of 1585 patients reported an overall estimated median prevalence of anti-b2GPI-DI antibodies of 44% in patients with APS and/or systemic lupus erythematosus (SLE), and a significant higher prevalence of anti-b2GPI-DI antibodies among APS patients compared to SLE alone [3] . The analysis focused on the IgG, while the roles of IgM and IgA need further investigation. Furthermore, when analyzing the thrombotic risk assessment associated with anti b2GPI-DI antibodies positivity, the study reported an overall OR 1.99; 95% CI 1.52-2.6; p \ .0001. Antib2GPI-DI antibodies may represent a promising tool when assessing thrombotic risk in APS patients.
Antiprothrombin and anti-phosphatidylserine/ prothrombin antibodies aPT and aPS/PT antibodies are directed against negatively charged phospholipids other than cardiolipin. aPT antibodies are commonly detected by ELISA, using prothrombin coated onto irradiated plates, or prothrombin in complex with phosphatidylserine. Although aPT and aPS/ PT antibodies can co-exist in the same patients, they are part of two different populations of autoantibodies. Currently, most of the studies in the literature support their role in helping defining APS diagnosis, as well as the association between antiprothrombin antibodies, in particular aPS/ PT, and the clinical manifestations of APS [4] . Available data are predominantly mainly focused on the IgG isotype, while the roles of IgA and IgM still need further clarifications. Although existing data are promising, further studies are needed to establish the real impact and clinical significance of these antibodies in routine testing.
aPL IgA
IgA aPL antibodies have a low prevalence, and in most cases, they are found along with other aPL, but they have failed to enhance the diagnostic accuracy when routinely tested.
To date, no conclusive prospective study has offered a clear view on the usefulness of IgA aPL antibodies testing, and their use is not a part of the current routine diagnostic algorithm. Nevertheless, isolated positivity for IgA antib2GPI might help to identify additional patients with thrombosis or pregnancy morbidity, recommending this test when other aPL are negative. Based on the present evidence, IgA aPL testing should be considered for thrombotic assessment risk only in selected patients, in particular when other aPL tests are negative, in the presence of clinical APS signs and/or symptoms, mainly associated with SLE.
Risk assessment and aPL
When assessing risk for clinical manifestations of APS, aPL titres as well as their single, double or triple presence, have all been suggested to have a different distinct significance [5] . In general, the presence of aPL in individuals without any clinical manifestations, i.e., aPL carriers, can be seen as a risk factor for first time thromboembolic events, and various studies have investigated the significance of aPL positivity and the occurrence of thrombotic events [6] .
In more detail, LA has been shown to be a better predictor for thrombosis compared to any other aPL, as described by a systematic review in 2003 by Galli et al., including 753 patients and 234 controls, which show that LA is a strong risk factors for both arterial and venous thrombosis [6] . On the other hand, De Groot et al. showed in their Leiden cohort that included 473 patients and 472 control subjects, that the presence of LA alone without the presence of anti-b2GPI (or antiprothrombin antibodies) was not significantly associated with a risk for a first deep vein thrombosis (DVT) (OR 1.3, 95% CI 0.3-6.0). However, in patients who tested positive for LA and anti-b2GPI antibodies (or antiprothrombin), the OR of a first time deep venous thrombosis increased to 10.1 (95% CI 1.3-79.8) [7] .
Regarding triple positivity, Pengo et al. demonstrated that the association of triple positive patients carries with it an increased risk of clinical manifestations of APS, both thrombosis and adverse pregnancy outcome, compared to patients with positivity for only one aPL [8] .
Otomo et al. [9] expanded on this principle, and have developed the aPL-score (aPL-s), to determine whether aPL titres influence the risk of thrombosis, comparing high to medium/low titres of aCL and anti-b2GPI IgG and IgM, respectively. The group reports that high levels of IgGaCL, anti-b2GPI (and also anti-phosphatidylserine and antiprothrombin antibodies) were closely related to the clinical manifestations of APS. In their study, the aPL-score correlates with a history of thrombosis or pregnancy morbidity. Moreover, the aPL-s score was shown to be of predictive value for the recurrence and/or new onset of thrombotic events.
In conclusion, different aPL profiles are an important indicator for risk assessment of APS clinical manifestations, and represent a fundamental tool for clinicians especially when managing aPL carriers.
Global APS score (GAPSS)
Moving toward the concept of aPL as a risk factor, our group recently published a comprehensive series of studies developing and validating the global APS score (GAPSS) in different patient populations [10] . The GAPSS score combines independent risk factors for thrombosis and pregnancy loss, taking into account aPL profiles (criteria aPL and non-criteria aPL), as well as conventional cardiovascular risk factors and autoimmune antibody profiles. Among all the computed variables (extensive aPL testing, cardiovascular risk factors evaluation, autoimmune profile), multivariate logistic regression analysis showed that only arterial hypertension, hyperlipidaemia, LA, aCLIgG and/or IgM, anti-b2GPI IgG, and/or IgM and aPS/PT IgG, and/or IgM were independent risk factors for thrombosis and/or pregnancy morbidity.
In brief, all variables were computed as dichotomized, to make GAPSS more widely adoptable. aPL positivity was assessed according to the updated APS classification criteria 1. The GAPSS includes IgG/IgMaCL (five points), IgG/IgM anti-b2GPI (four points), LA (four points), IgG/ IgM anti-phosphatidylserine-prothrombin complex antibodies (three points), hyperlipidaemia (three points), and arterial hypertension (one point).
The GAPSS model was developed in patients with SLE, and higher GAPSS scores were observed in patients who experienced thrombosis and/or pregnancy loss compared with those without clinical events. Moreover, the GAPSS score was evaluated in a subsequent prospective study of 51 SLE patients [10] , and in 62 consecutive patients with primary APS [11] . The GAPSS model was further applied and validated by two independent groups that described APS manifestations (thrombosis or pregnancy morbidity), and were experienced by patients with higher GAPSS values compared to patients without APS manifestations [10] .
New therapeutic options beyond anti-coagulation with vitamin K antagonists
Long-term anti-coagulation with Vitamin K antagonists (VKA) is currently the therapeutic option for thrombotic APS management. Table 1 summarizes the current strategies for management of patients with aPL. However, therapy with VKA raises many challenges for clinicians and patients, including adherence to compliance with treatment, dietary interactions and impacts on daily life. Besides, patients with APS may experience clinical manifestations not directly related to thrombotic pathogenesis that may not respond to anti-coagulation (e.g., from systemic symptoms such as fatigue to organ specific manifestations as cardiac valves involvement). Moreover, the monitoring of anti-coagulation with VKA in LA positive patients can be challenging, as the responsiveness of the reagents used in the INR testing varies widely, leading to potential instability of anti-coagulation. For the above reasons, new therapeutic options for APS management are highly needed.
Hydroxychloroquine
Clinical trials and animal models supported the role of hydroxychloroquine (HCQ) as a useful tool to reduce the risk of thrombosis [12] . The various antithrombotic mechanisms include inhibition of platelet aggregation and adhesion, cholesterol lowering mechanisms, and blockade of aPL production [12] .
In a recent trial, Rand et al. [13] showed that HCQ significantly reduces both the binding of aPL-b2GPI complexes to phospholipid surfaces and the binding of the individual proteins to bilayers. The same group reports in a further study [13] that HCQ also caused modest, but statistically significant, reductions of clinical aPL titers as well as a reduction of the disruption by aPL of the annexin A5 anti-coagulant shield.
Both retrospective and prospective studies demonstrated a beneficial effect of HCQ on primary thrombosis prevention in aPL-positive patients. More in detail, Kaiser et al. [14] enrolled in a large cohort of 1930 SLE patients, confirmed that HCQ use was protective for thrombosis. However, a recent randomized multicenter study (https:// clinicaltrials.gov/ct2/show/NCT01784523) investigating the prophylactic role of HCQ against thrombosis in patients with aPL has been terminated early due to a low recruitment rate exacerbated by manufacturing shortage and price increase of HCQ, pointing out the challenges of designing prospective randomized trials in these conditions.
Rivaroxaban in anti-phospholipid syndrome (RAPS)
The use of the novel anti-coagulants would be expected to improve the quality of life of APS patients. These agents, in fact, have fewer drug interactions and dietary restrictions compared with VKA, and very predictable anti-coagulant effects with fixed dosing regiments, making it unnecessary to routinely monitor anti-coagulant intensity. However, the lack of INR monitoring may represent a downfall of novel anti-coagulant therapy, introducing variability in patients' adherence compliance.
Rivaroxaban (a direct anti-X agent) has been approved by the European Medicines Agency for the prevention of stroke and systemic embolism in patients with atrial fibrillation, and for venous thromboembolic events management. Rivaroxaban in anti-phospholipid syndrome (RAPS) was a randomized, controlled, open-label, phase 2/3, non-inferiority trial, that included 116 APS patients who were taking VKA for previous venous thromboembolism, with a target international normalized ratio of 2.5 [15] . Patients were randomized to receive warfarin or 20 mg oral rivaroxaban daily. Treatment effect was measured as the ratio of rivaroxaban to warfarin for thrombin generation. Endogenous thrombin potential for rivaroxaban did not reach the non-inferiority threshold, but as there was no increase in thrombotic risk compared with standard-intensity warfarin. No thrombosis or major bleeding was seen. Serious adverse events occurred in four patients. In brief, the first was an intracranial haemorrhage that pre-dated the trial; the second was an episode of abdominal pain, vomiting, arthralgia, and myalgia. Two were judged to be unrelated to the trial drug: the first was a suspected deep vein thrombosis at day 176, the second was intestinal perforation. Patient's bleeding risk should be estimated before prescribing high-intensity anti-coagulant or combined anti-aggregant-anti-coagulant therapy Non-SLE patients with a first non-cardioembolic cerebral arterial event, with a low-risk aPL profile and the presence of reversible trigger factors could individually be considered candidates for treatment with antiplatelet agents Duration of treatment Indefinite antithrombotic therapy is recommended in patients with definite APS and thrombosis aPL anti-phospholipid antibody, APS anti-phospholipid syndrome, INR international normalized ratio, LMWH low-molecular-weight heparin, SLE systemic lupus erythematosus a High-risk aPL profile: lupus anti-coagulant positivity, triple positivity (lupus anti-coagulant ? anti-cardiolipin ? anti-bb2-glycoprotein I antibodies)
Rivaroxaban might be an effective alternative in patients with APS and previous venous thromboembolism. Its use in APS patients with arterial events and/or high risk aPL profile needs further investigation. To date, at least other three trials (RAPS-Canada, TRAPS (https://clinicaltrials. gov/ct2/show/NCT02157272) and ASTRO-APS (https:// clinicaltrials.gov/ct2/show/NCT02295475) are currently further investigating the use of direct new oral anti-coagulants in patients with APS and results are highly waited.
IVIG
Evidences support the efficacy of IVIG in addition to conventional therapy, in primary and secondary APS patients, in preventing the occurrence of further thromboembolic events [16] . Despite the promising observations especially in patients with the so-called APS plus (APS with ANA positivity and sign/symptoms of a connective tissue disease not fulfilling the classification criteria) further data are need to establish indications and optimal doses of IVIG in thrombotic APS patients.
B-cells depletion therapy
While immunosuppressive drugs such as i.v. cyclophosphamide may be helpful in patients with active systemic autoimmune diseases, mainly SLE and systemic vasculitis, their use in APS is still controversial, and limited to very selected case of catastrophic APS (CAPS) or in severe cases refractory to standard therapy. Some case reports about the use of rituximab, an anti-CD20 monoclonal antibody, in the treatment of APS have been published [17] .
B cells are likely to play a central role in the generation of the aPL-induced clinical manifestations of the disease, so they might constitute a logical therapeutic target in APS. Anecdotally, its use has also been associated with a downregulation of aPL titers [18] . A pilot open-label phase II trial of RTX for non-criteria manifestations of APS (such as thrombocytopenia, skin ulcers, nephropathy, and cognitive dysfunction) concluded that RTX may represent a well-tolerated option in the therapeutic arsenal for APS. However, it has been reported to be effective in controlling some but not all non-criteria manifestations of APS. Overall, although more data are necessary to support the use of these drugs in the setting of severe APS, current experience seems quite promising, especially in patients with severe thrombocytopenia. Table 2 summaries our experience with cyclophosphamide and/or rituximab in very life-threatening cases refractory to standard therapies. Of note, two patients have been treated with an Intensified B-Cell Depletion Therapy (IBCDT), an approach we employed as a rescue therapy in refractory lupus nephritis or systemic vasculitis. IBCDT consists of ''four (weekly) 
Conclusion
APS remains a substantial diagnostic challenge for physicians, mainly due to the expanding range of reported clinical manifestations associated with the presence of aPL as well as to the limitations of current laboratory testing. Although it is the physician taking care of the patient who ultimately makes the diagnosis, laboratory-testing still plays a key role in many phases of the management of APS patients. While it is widely accepted that aPL play a crucial pathogenic role in inducing clinical manifestations, limitations exist in detailed knowledge by both clinical and laboratory perspectives regarding the ''complete'' range of available aPL tests, as well as ongoing problems with assay reproducibility and standardization.
To date, aPL profiling represents the most accurate risk stratification tool for thrombosis. The so-called ''triple positivity'' was found to be associated with thrombosis in up to 87% of cases of APS, while in the other profiles the association was around 50% [20] . With regard to risk stratification, some scoring systems have been proposed to help physicians to identify the individual risk of thrombosis/pregnancy morbidity in patients positive for aPL; among others, the GAPSS, which brings together the aPL profile (including both criteria and non-criteria aPL) and traditional cardiovascular risk factors, seems a promising tool to identify patients at higher risk of new events. Referring to treatments, while current therapeutic options remain confined to long-term anti-coagulation with VKA, the future holds much promise with the identification of novel potential targets, many of which are currently under investigation. The challenge will be to design prospective randomized controlled clinical trials to provide the evidence necessary to support integration of these therapies into clinical practice. Ideally, the task for the future will be to tailor the APS management, taking into account aPL profile and clinical manifestations.
Compliance with ethical standards
Conflict of interest The Authors declare that they have no conflict of interest.
Statement of human and animal rights Not applicable.
Informed consent Not applicable.
Funding None declared.
